Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Pancreatic cancer
Closed
Phase 2
This trial is looking at a new drug called LY2495655 to treat muscle loss and weakness in people with pancreatic cancer that has spread into nearby tissue () or to another part of the body.
People with advanced cancer often have loss of muscle and muscle weakness. Currently there is no treatment for this. This trial is looking at a drug called LY2495655 to help stop muscle loss and weakness.
LY2495655 works by blocking a substance (protein) called myostatin. Myostatin controls muscle growth in the body. By blocking it, the researchers hope LY2495655 will help control muscle loss and weakness.
The researchers will be looking at LY2495655 in combination with chemotherapy for advanced pancreatic cancer. The trial drug will not be treating the cancer itself.
The aims of this trial are to find out
How safe LY2495655 is
What are the side effects are when you have it with chemotherapy
Recruitment start: 22 November 2012
Recruitment end: 20 December 2013
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Kenneth Fearon
Eli Lilly and Company Limited
Experimental Cancer Medicine Centre (ECMC)
National Institute for Health Research Cancer Research Network (NCRN)
Last reviewed: 23 November 2015
CRUK internal database number: 9280
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
